HealthEquity Enterprise Value Over E B I T D A from 2010 to 2024

HQY Stock  USD 103.57  0.19  0.18%   
HealthEquity Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, HealthEquity Enterprise Value Over EBITDA regression line of annual values had r-squared of  0.35 and arithmetic mean of  30.16. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
24.7722867
Current Value
26.67
Quarterly Volatility
14.54372845
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check HealthEquity financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HealthEquity's main balance sheet or income statement drivers, such as Depreciation And Amortization of 160.7 M, Interest Expense of 58.2 M or Selling General Administrative of 108.8 M, as well as many indicators such as Price To Sales Ratio of 6.57, Dividend Yield of 0.0735 or PTB Ratio of 5.64. HealthEquity financial statements analysis is a perfect complement when working with HealthEquity Valuation or Volatility modules.
  
Check out the analysis of HealthEquity Correlation against competitors.
For more information on how to buy HealthEquity Stock please use our How to Invest in HealthEquity guide.

Latest HealthEquity's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of HealthEquity over the last few years. It is HealthEquity's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HealthEquity's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

HealthEquity Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean30.16
Geometric Mean25.79
Coefficient Of Variation48.22
Mean Deviation12.30
Median32.32
Standard Deviation14.54
Sample Variance211.52
Range45.3312
R-Value0.59
Mean Square Error148.66
R-Squared0.35
Significance0.02
Slope1.92
Total Sum of Squares2,961

HealthEquity Enterprise Value Over E B I T D A History

2024 26.67
2023 24.77
2022 34.27
2021 50.75
2020 44.99
2019 44.92
2018 37.16

About HealthEquity Financial Statements

HealthEquity investors use historical fundamental indicators, such as HealthEquity's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in HealthEquity. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 24.77  26.67 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for HealthEquity Stock Analysis

When running HealthEquity's price analysis, check to measure HealthEquity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HealthEquity is operating at the current time. Most of HealthEquity's value examination focuses on studying past and present price action to predict the probability of HealthEquity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HealthEquity's price. Additionally, you may evaluate how the addition of HealthEquity to your portfolios can decrease your overall portfolio volatility.